KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Market Cap	62.96B -24.9%
Revenue (ttm)	126.26B -2.9%
Net Income	3.45B -62.1%
EPS	60.02 -62.1%
Shares Out	57.45M
PE Ratio	18.26
Forward PE	40.59
Dividend	52.00 (4.74%)
Ex-Dividend Date	Mar 30, 2026

Volume	231,700
Open	1,106.00
Previous Close	1,113.00
Day's Range	1,089.00 - 1,113.00
52-Week Range	1,091.00 - 1,725.00
Beta	-0.05
Analysts	Sell
Price Target	1,100.00 (+0.37%)
Earnings Date	Jul 30, 2026

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1923
• Employees: 1,998
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4569

Financial Performance

In fiscal year 2026, KYORIN Pharmaceutical's revenue was 126.26 billion, a decrease of -2.94% compared to the previous year's 130.09 billion. Earnings were 3.45 billion, a decrease of -62.05%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error